A-31S is under clinical development by Nektr Technologies and currently in the Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect A-31S’s likelihood of approval (LoA) and phase transition for Onychomycosis (Tinea Unguium) took place on 30 Nov 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their A-31S Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

A-31S overview

A-31S (Mycosinate) is under development for the treatment of Onychomycosis, Enterococcus faecium infections, Staphylococcus aureus infections, Klebsiella pneumoniae infections, Acinetobacter baumannii infections, Pseudomonas aeruginosa infections, Neisseria Gonorrhoeae, Cutibacterium Acnes, Enterococcus Faecalis, Escherichia coli infections, Neisseria Gonorrhoeae infections, Cutibacterium Acnes infections, Beta Haemolytic Streptococci Group A infections, Altenaria, Aspergillus species, Blastomyces dermatitidis infections, Candida auris infections, Coccidioides species, Cryptococcus neoformans, Curvularia species, Exophialia, Exserohilum, Fusarium species, Pneumocystis species, Rhizopus arrhizus infections, Scedosporium species, Trichophyton Interdigitale infections, Trichophyton rubrum infections. It is administered topically. The drug candidate is administered by topical route as a gel. The drug candidate is based on Mycosinate platform technology.

Nektr Technologies overview

Nektr Technologies is a biotechnology company that discovers and develops anti-bacterial, anti-fungal, anti-viral, intracellular simulation solutions. It offers A3IS, a non-antibiotic alternative biological modulation platform that creates reactive oxygen species (ROS) to restore and eliminate organisms. The company’s A3IS technology is also used to treat infected skin lacerations, chronic wounds and dermatological conditions. Nektr Technologies Mycosinate platform is used to treat onychomycosis, a fungal nail infection caused by the dermatophyte trichophyton rubrum and associated pathogens. The company’s technologies find application in hive health, biofuel production, water purification, animal health and crop diseases. Nektr Technologies is headquartered in Sligo, Ireland.

Quick View A-31S LOA Data

Report Segments
  • Innovator
Drug Name
  • A-31S
Administration Pathway
  • Topical
Therapeutic Areas
  • Infectious Disease
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.